Evidence map›Paper›PMID 37211864›Full record

ArticleCancer biology & therapy2023

LINC01060 knockdown inhibits osteosarcoma cell malignant behaviors

Qiang Zhang, Xinqiao Tang, Yi Zhou, Xiaoming Chen, Ke Peng, Ruizhong Jiang, Zhong Liu, Xiaoxia Song, Hong Xia

Open access · goldAbstract read
In one paragraph

Article in Cancer biology & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. CXCL10-induced chemotaxis ofMolecular therapy. Oncology · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Qiang ZhangDepartment of Orthopedics, Xiangtan Central Hospital, Xiangtan, Hunan, China.ORCID 0000-0001-5817-9494
Xinqiao TangDepartment of Orthopedics, Xiangtan Central Hospital, Xiangtan, Hunan, China.
Yi ZhouDepartment of Orthopedics, Xiangtan Central Hospital, Xiangtan, Hunan, China.
Xiaoming ChenDepartment of Orthopedics, Xiangtan Central Hospital, Xiangtan, Hunan, China.
Ke PengDepartment of Spine Surgery, Xiangtan Central Hospital, Xiangtan, Hunan, China.
Ruizhong JiangDepartment of Orthopedics, Xiangtan Central Hospital, Xiangtan, Hunan, China.
Zhong LiuDepartment of Orthopedics, Xiangtan Central Hospital, Xiangtan, Hunan, China.
Xiaoxia SongDepartment of Respiratory Medicine, Xiangtan Central Hospital, Xiangtan, Hunan, China.
Hong XiaDepartment of Orthopedics, Xiangtan Central Hospital, Xiangtan, Hunan, China.
Xiangyang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite its low frequency, osteosarcoma is one of the deadliest malignancies in children and adolescents. The phosphatidylinositol 3-kinase (PI3K)/Akt signaling activation and epithelial-to-mesenchymal transition (EMT) are critical issues during osteosarcoma development. This study found long intergenic non-protein coding RNA 1060 (LINC01060) to be an EMT-related long non-coding RNA (lncRNA) up-regulated in osteosarcoma; higher LINC01060 expression was linked to a worse prognosis in osteosarcoma patients.

Indexed as

Bone NeoplasmsOsteosarcomaAdolescentCell Line, TumorCell MovementCell ProliferationChildEpithelial-Mesenchymal TransitionHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, UntranslatedPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Untranslatedepithelial-to-mesenchymal transition (EMT)LINC01060metastasisOsteosarcomathe PI3K/akt signaling

Identifiers

PMID37211864
PMCPMC10208149
OpenAlexW4377219964

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.